Slide 1: Welcome to the 1Q24 webinar
Welcome to the 1Q24 webinar April 29, 2024
Slide 2: Speaking at today’s webinar
Speaking at today’s webinar 2
Slide 3: This is Modulight
This is Modulight We fight cancer with science and technology ▪ We are a biomedical company ▪ We also manufacture products that designs and manufactures for other high-value applications laser devices for the treatment such as flow cytometry, quantum of cancer and eye diseases and computing and digi
Slide 4: Today’s agenda
Today’s agenda ▪ 1Q24 in brief ▪ R&D pipeline ▪ Geographical expansion ▪ Financial highlights ▪ Customer base ▪ Revenue model, PPT & economics ▪ Outlook ▪ Summary ▪ Q&A 4
Slide 5: 1Q24 in brief
1Q24 in brief ▪ Implementation of the PPT business model expanded in several indications & customers ▪ Two new pharmaceutical customers and a prototype order for our generic laser platform from a new biomedical Year 2024 started customer well with the ▪ 28 projects in R&D pipeline (27); focused expa
Slide 6: Solid R&D pipeline
Solid R&D pipeline Number of projects with commercialization potential ▪ Accelerated implementation of PPT business model across 30 several indications & customers ▪ Focused on advancing especially 25 the projects currently in P3 trials 20 ▪ 28 projects ▪ 2 new pharmaceutical customers 15 acquired d
Slide 7: Geographical expansion
Geographical expansion ▪ Focus on expanding business in the US: hiring a local sales director has increased our speed in local business development ▪ Europe and Asia: cooperation with new strategic distribution partnerships and expect to continue to widen the network further later this year ▪ Two ne
Slide 8: Financial highlights January–March 2024
Financial highlights January–March 2024 ▪ Revenue EUR 1.1 million was affected by transition to PPT business model: revenue initially Revenue EBITDA EBIT generated more slowly ▪ EBITDA increased to EUR -1.3 million due to improved efficiency, despite continued increased EUR EUR EUR investments in pr
Slide 9: Key figures
Key figures Group EUR 1,000 unless otherwise noted 1–3/2024 1–3/2023 1–12/20231) Revenue 1,059 1,493 4,025 EBITDA -1,314 -1,429 -8,539 EBITDA - % -124.1% -95.7% -212.1% Operating result (EBIT) -1,978 1,903 -12,132 Operating result (EBIT) - % -186.8% -127.5% -301.4% Earnings for the period -1,872 1,7
Slide 10: Modulight’s customer base
Modulight’s customer base Customer maturity Customer ownership continues to improve 30 ▪ 36% have over 1bn revenue 25 ▪ 68% of customers are listed 20 companies 15 ▪ 61% are established companies 10 ▪ 25% are privately owned 5 ▪ 7% are research companies 0 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q2
Slide 11: Revenue model
Revenue model The objective is revenue, based on the Customized R&D projects based on the Best Efforts share of pharmaceutical or Pay Per principle, without revenue risk for Modulight Treatment fees, or the utilization rate of industrial applications. Predictability of Modulight’s revenue is improvi
Slide 12: Pay Per Treatment business model update
Pay Per Treatment business model update ▪ Popularity of PPT business model has increased, and customers who have adopted Our PPT model has grown it are expanding their use of our services in popularity, and customers who have ▪ Continued expanding PPT model adoption adopted it are expanding in cance
Slide 13: US healthcare market economics
US healthcare market economics ▪ To support the implementation of pay-per-treatment business models, we have studied & analysed the costs related to current standard of care in the US with KPMG for 11 indications in oncology and ophthalmology For cancer diseases, weighted average for standard of car
Slide 14: Outlook
Outlook Modulight has not issued guidance for revenue or profitability in 2024. As the company’s customer projects are still distributed across varying early stages of development, and predicting developments in the market remains challenging, it is difficult to forecast performance in 2024. However
Slide 15: Summary
Summary ▪ R&D pipeline at 28 projects and progressing ▪ PPT business model implemented in with several indications & customers within the R&D pipeline ▪ Focus on advancing projects towards commercialization (phase 3) ▪ 2 new pharmaceutical customers during 1Q24 likely to bring new projects to R&D pi
Slide 16: Thank you! Questions?
Thank you! Questions? @ ©O@ @® modulight